Meng Mei
Research Subjects
Meng Mei has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Hui Peng
Wuhan Children’s Hospital, Tongji Medical College, and
1 shared publication - Jing Peng
Department of Pharmacy, Wuhan Children’s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication Maochang Liu
Department of pharmacy, China
1 shared publication- Qiaoling Li
Department of Pharmacy, Wuhan Children’s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication - Rong Zhou
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
1 shared publication - Xinlin Li
Department of Pharmacy, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430015, China
1 shared publication
Latest Publications
- Open Access
- 11 July 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1632361
Application of cell-derived vesicle-based biomimetic drug delivery system in tumor therapy
Cell-derived vesicles play a crucial role in intercellular information transmission and serve as vital carriers facilitating cell-to-cell communication. These vesicles contain specific biological information from their parental cells, enabling them to transport proteins, cytokines, mRNA, and DNA to other cells or organs. Presently, cell-derived vesicles have extensive application in inhibiting tumor growth and metastasis, as well as in tumor diagnosis and early screening. Numerous studies have highlighted the potential of cell-derived vesicles as drug delivery systems, showcasing advantages such as enhanced biocompatibility, natural active targeting, improved systemic circulation, and greater efficacy compared to conventional drug delivery carriers. In this article, we aim to explore the utilization of cell-derived vesicles as drug delivery systems in tumor therapy, focusing on various drug-loading techniques and analyzing the advantages and characteristics of different types of cell-derived vesicles. Our findings will provide valuable assistance in the development of drug delivery systems based on these vesicles.
- 11 July 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1632361
Open AccessApplication of cell-derived vesicle-based biomimetic drug delivery system in tumor therapy
Cell-derived vesicles play a crucial role in intercellular information transmission and serve as vital carriers facilitating cell-to-cell communication. These vesicles contain specific biological information from their parental cells, enabling them to transport proteins, cytokines, mRNA, and DNA to other cells or organs. Presently, cell-derived vesicles have extensive application in inhibiting tumor growth and metastasis, as well as in tumor diagnosis and early screening. Numerous studies have highlighted the potential of cell-derived vesicles as drug delivery systems, showcasing advantages such as enhanced biocompatibility, natural active targeting, improved systemic circulation, and greater efficacy compared to conventional drug delivery carriers. In this article, we aim to explore the utilization of cell-derived vesicles as drug delivery systems in tumor therapy, focusing on various drug-loading techniques and analyzing the advantages and characteristics of different types of cell-derived vesicles. Our findings will provide valuable assistance in the development of drug delivery systems based on these vesicles.
- Open Access
- 3 February 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (2) , 262
Microglia PKM2 Mediates Neuroinflammation and Neuron Loss in Mice Epilepsy through the Astrocyte C3-Neuron C3R Signaling Pathway
Epilepsy is a neurological disease and approximately 30% of patients have failed to respond to current anti-epilepsy drugs. The neuroinflammation mechanism has raised increasing concerns and been regarded as the novel treatment strategy in epilepsy, but the target molecules require further research. Pyruvate kinase isoform 2 (PKM2) is well studied in peripheral inflammation, but its role in epilepsy neuroinflammation remains unclear. We knocked down microglia PKM2 in the hippocampus using a stereotaxic adeno-associated virus (AAV) microinjection and established a pilocarpine-induced status epilepticus (PISE) model. Racine score was used to evaluate the seizure grade. Next, we used WB, Multiplex tyramide signal amplification (TSA) staining and other methods to determine neuroinflammation and the complement component 3 (C3)–C3aR interaction in primary microglia. Results showed that microglia PKM2 knockdown reduced epilepsy grade and rescued neuron loss. Mechanistically, PKM2 knockdown inhibited microglia activation and inflammation factor secretion through suppressing p65 expression and phosphorylation. The reduced microglia C1q, TNF-α, and IL-1α were responsible for the decreased astrocyte C3 expression and the following neuron damage caused by the C3–C3aR interaction. Our data suggest that microglia PKM2 inhibition ameliorates neuroinflammation and neuron loss through C3-C3aR interaction in epilepsy, which provides an attractive target for the intervention of damaged neuron-glia crosstalk in epilepsy.
- 3 February 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (2) , 262
Open AccessMicroglia PKM2 Mediates Neuroinflammation and Neuron Loss in Mice Epilepsy through the Astrocyte C3-Neuron C3R Signaling Pathway
Epilepsy is a neurological disease and approximately 30% of patients have failed to respond to current anti-epilepsy drugs. The neuroinflammation mechanism has raised increasing concerns and been regarded as the novel treatment strategy in epilepsy, but the target molecules require further research. Pyruvate kinase isoform 2 (PKM2) is well studied in peripheral inflammation, but its role in epilepsy neuroinflammation remains unclear. We knocked down microglia PKM2 in the hippocampus using a stereotaxic adeno-associated virus (AAV) microinjection and established a pilocarpine-induced status epilepticus (PISE) model. Racine score was used to evaluate the seizure grade. Next, we used WB, Multiplex tyramide signal amplification (TSA) staining and other methods to determine neuroinflammation and the complement component 3 (C3)–C3aR interaction in primary microglia. Results showed that microglia PKM2 knockdown reduced epilepsy grade and rescued neuron loss. Mechanistically, PKM2 knockdown inhibited microglia activation and inflammation factor secretion through suppressing p65 expression and phosphorylation. The reduced microglia C1q, TNF-α, and IL-1α were responsible for the decreased astrocyte C3 expression and the following neuron damage caused by the C3–C3aR interaction. Our data suggest that microglia PKM2 inhibition ameliorates neuroinflammation and neuron loss through C3-C3aR interaction in epilepsy, which provides an attractive target for the intervention of damaged neuron-glia crosstalk in epilepsy.